“Capsules are elongated, soft, gelatinous, longitudinally differentiated in color, one side is pink, the other is cream-white, they contain a paste of pink color with the smell of vanilla.
Drug substance and its quantity
Medicinal substances: benfotiamin 40 mg, pyridoxine hydrochloride 90 mg, cyanocobalamin 250 μg in one capsule.
Excipients: solid fat, refined rapeseed oil, soy lecithin, ethyl vanillin, calcium hydrophosphate, gelatin, glycerin 85%, sorbitol, titanium dioxide (Е 171), iron oxide red (Е 172).
How to use
Recommended dose
1 tablet, coated, 3 times a day.
In more light cases or during the recovery period, 1-2 coated tablets per day are sufficient.
Таблетки, покрытые уплачной, swallow whole, not chewing, drinking a small amount of liquid.
What should be остерегаться
If you suffer from psoriasis (psoriasis), you can start taking Milgamma H only after consulting a doctor, because vitamin B12 can aggravate skin manifestations.
If you suffer from cancer, you should not take this product.
Не примирайте Мильгамму Н.
if you are allergic to benfotiamine, pyridoxine, cyanocobalamin, peanuts, soy or any other component of this product. Precautions and precautions
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, suspect that you are pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking this medicine. It is not recommended to use Milgam Н during pregnancy and breastfeeding.
Мильгамма Н contains sorbitol.
If your doctor told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Carefully read the insert included in each package.”
HORIEN solution for soft contact lenses 500ml,HORIEN Roztok na kontaktní čočky 500 ml
£20.64
Analergin 10 mg Cetirizine 10 tablets,Analergin 10 mg Cetirizin 10 Tabletten
£4.99
MILGAMMA N cps 20,MILGAMMA N 20 měkkých tobolek
£23.72
A preparation containing a combination of group B vitamins (B1 and B12). It is used as a supportive treatment in diseases affecting the peripheral nervous system.

